Palmitoylethanolamide for Nickel Allergy: Plausible, Untested, and Worth Considering
ReviewHumans
- Design
- Review
- Subjects
- Not applicable; this is a viewpoint paper, not a study
- Dose used in the study
- Not applicable; this is a viewpoint paper, not a study
- Duration
- Not applicable; this is a viewpoint paper, not a study
- What was measured
- Why palmitoylethanolamide could be worth considering for nickel allergy: PPAR-alpha signalling, mast cell stabilisation, VEGF expression and gut barrier integrity as candidate mechanisms, with no new experimental data
What the authors reported
The authors propose that PEA, through PPAR-alpha signalling, mast cell stabilisation, reduced VEGF expression and improved gut barrier integrity, could address nickel allergic contact dermatitis and systemic nickel allergy syndrome. They frame this as a viewpoint meant to raise questions rather than give definitive answers, and call for experimental and clinical studies.
Limits of this study
A viewpoint/hypothesis paper with no new data; the authors state PEA's use for nickel allergy is untested. It cannot show effect in people until such studies are done. The authors declare no conflicts of interest.
Source
PubMed 41595711 · doi:10.3390/biomedicines14010177
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.